Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans

• Published in: Medicine and science in sports and exercise 2010-04, Vol.42 (4), p.739-744
• Main Authors: Richards, Jennifer C, Lonac, Mark C, Johnson, Tyler K, Schweder, Melani M, Bell, Christopher
• Format: Article
• Language: English
• Subjects: Adult; Antioxidants - pharmacology; Catechin - analogs & derivatives; Catechin - pharmacology; Double-Blind Method; Female; Humans; Male; Maximal Voluntary Ventilation - drug effects; Oxygen Consumption - drug effects; Physical Endurance - drug effects; Physical Endurance - physiology; Space life sciences; Young Adult
• ISSN: 0195-9131; 1530-0315
• DOI: 10.1249/MSS.0b013e3181bcab6c

Epigallocatechin-3-gallate (EGCG), a component of green tea, increases endurance performance in animals and promotes fat oxidation during cycle ergometer exercise in adult humans. We have investigated the hypothesis that short-term consumption of EGCG delays the onset of the ventilatory threshold (VT) and increases maximal oxygen uptake (VO2max). In this randomized, repeated-measures, double-blind study, 19 healthy adults (11 males and 8 females, age = 26 ± 2 yr (mean ± SE)) received seven placebo or seven EGCG (135-mg) pills. Forty-eight hours before data collection, participants began consuming three pills per day; the last pill was taken 2 h before exercise testing. VT and VO2max were determined from breath-by-breath indirect calorimetry data collected during continuous incremental stationary cycle ergometer exercise (20-35 W·min(-1)), from rest until volitional fatigue. Each condition/exercise test was separated by a minimum of 14 d. Compared with placebo, short-term EGCG consumption increased VO2max (3.123 ± 0.187 vs 3.259 ± 0.196 L·min(-1), P = 0.04). Maximal work rate (301 ± 15 vs 301 ± 16 W, P = 0.98), maximal RER (1.21 ± 0.01 vs 1.22 ± 0.02, P = 0.27), and maximal HR were unaffected (180 ± 3 vs 180 ± 3 beats·min(-1), P = 0.87). In a subset of subjects (n = 11), maximal cardiac output (determined via open-circuit acetylene breathing) was also unaffected by EGCG (29.6 ± 2.2 vs 30.2 ± 1.4 L·min(-1), P = 0.70). Contrary to our hypothesis, EGCG decreased VO2 at VT (1.57 ± 0.11 vs 1.48 ± 0.10 L·min(-1)), but this change was not significant (P = 0.06). Short-term consumption of EGCG increased VO2max without affecting maximal cardiac output, suggesting that EGCG may increase arterial-venous oxygen difference.